HIV cure studies have led to many disappointments, but researchers continue to explore ways to achieve sustained viral remission—and more funding can help. The National Institutes of Health recently awarded approximately $53 million in annual funding over the next five years to organizations that make up the Martin Delaney Collaboratories for HIV Cure Research, upping the total amount by about 75% and expanding the number of institutions from six to 10. The awards will focus on three key areas: basic research on HIV reservoirs and posttreatment control; strategies for delaying viral rebound; and approaches for reducing, eradicating or inactivating latent virus. One of the grants will focus on infants and children. Separately, amfAR, The Foundation for AIDS Research, has awarded nearly $600,000 to three teams exploring cutting-edge gene therapies for HIV cure research. These include engineered natural killer cells (following up on work on CAR-T cell therapy), broadly functional antibodies and CRISPR/Cas9 gene-editing technology.